Zydus Lifesciences is currently trading at RS 1002.10, up by 23.85 points or 2.44% from its previous closing of RS 978.25 on the BSE.

The stock opened at RS 986.85 and has touched an intraday high of RS 1003.20 and a low of RS 976.20. So far, 9,981 shares have been traded on the counter.

The BSE Group 'A' stock, with a face value of RS 1, has recorded a 52-week high of RS 1323.90 on August 9, 2024, and a 52-week low of RS 769.10 on February 9, 2024. The stock's one-week high and low stood at RS 1003.20 and RS 945.00, respectively. The company's current market capitalization is RS 98,434.84 crore.

Promoters hold a 74.98% stake in the company, while institutional investors and non-institutional investors hold 18.18% and 6.84%, respectively.

In its Q3FY25 earnings report, Zydus Lifesciences reported a 4.49% rise in net profit to RS 470.6 crore, compared to RS 450.4 crore in the same quarter last year. The company's total income increased by 4.65% to RS 2593.4 crore, compared to RS 2478.1 crore in Q3FY24.

On a consolidated basis, net profit surged 29.62% to RS 1023.5 crore for the quarter ended December 31, 2024, compared to RS 789.6 crore in the previous year. The total consolidated income rose by 17.25% to RS 5326.6 crore in Q3FY25, up from RS 4542.9 crore in the same period last year.